METHOD FOR ACTIVATION OF MAIN AND ADDITIONAL OUTFLOW TRACTS OF INTRAOCULAR FLUID IN GLAUCOMA Russian patent published in 2025 - IPC A61F9/07 A61F9/08 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to ophthalmology. Method for activation of main and additional pathways of intraocular fluid outflow in glaucoma consists of two stages, at the first stage, the conjunctiva is incised at the limb, the conjunctiva and Tenon's membrane are separated from the sclera, bipolar diathermocoagulation of the surface vessels of the sclera is performed, a superficial scleral flap is cut out with its base to the limb, and the Schlemm canal (SC) is opened. By means of 3 vertical incisions parallel to the limb to the ciliary body, the deep layers of the sclera are divided into 3 parts: front part of size 4×2 mm, middle part – scleral flap of size 4×1 mm and rear part of size 4×1 mm, all layers of sclera are removed in anterior part, leaving 0.5 mm of thickness of scleral tissue on surface of ciliary body. SC is opened, and the endothelial lining of the inner wall of the SC is removed. Further, the ciliary body is detached with a spatula from the middle and posterior parts of the sclera, creating a cyclodialysis cleft, from the scleral flap formed is an autoscleral drainage of size 4×1.5 mm, turn it through 90° and implanted into the created cyclodialysis cleft so that its front end is in the anterior scleral bed at distance of 1 mm from the inner wall of the SC, and the body is under the scleral bridge, and the posterior end is under the sclera in the suprachoroidal space. Then, a posterior portion of the deep layers of the sclera is removed, exposing the ciliary body and scleral drainage; the superficial flap is put in place and fixed. At the second stage, one hole is created in the trabecular apparatus in the area of the first stage of the given operation with a YAG laser and a single-mirror gonioscopy lens.

EFFECT: method enables to activate the uveoscleral outflow tract of IOF for a long period of time, to achieve a stable hypotensive effect, to reduce the number of antihypertensive agents, reducing the number of intra- and postoperative complications, reducing the length of staying in hospital and enabling the delayed YAG-laser trabeculopuncture.

1 cl, 2 ex